EveryONE Medicines Company Profile

Background

EveryONE Medicines is a biotechnology firm dedicated to developing individualized precision therapeutics for children afflicted with severe neurodegenerative diseases caused by unique genetic mutations. The company's mission is to design, develop, and manufacture personalized antisense oligonucleotide (ASO) medicines on a global scale, aiming to treat life-threatening conditions that currently lack effective therapies. By focusing on creating a scalable and sustainable system, EveryONE Medicines seeks to make individualized treatments accessible to patients worldwide.

Key Strategic Focus

EveryONE Medicines specializes in the rapid development of ASO therapies tailored to specific genetic variants responsible for rare neurodegenerative diseases in children. The company leverages proprietary AI-driven design processes to create these individualized medicines efficiently. By building a comprehensive ASO library, EveryONE Medicines aims to provide immediate matches for known genetic variants and develop custom therapies for newly discovered mutations. The primary markets targeted include pediatric patients with ultra-rare genetic conditions, addressing a significant unmet medical need.

Financials and Funding

Founded in 2020, EveryONE Medicines has secured seed funding from notable investors, including GV (formerly Google Ventures), Khosla Ventures, and Third Rock Ventures. The capital raised is intended to support the research, development, and commercialization of individualized ASO therapies, as well as to establish a new regulatory pathway for these treatments.

Pipeline Development

EveryONE Medicines is currently focused on the clinical-stage development of multiple ASO therapies targeting various genetic variants causing severe neurodegenerative diseases in children. The company is actively working with regulatory agencies across Europe to advance its clinical trial strategy and establish a new pathway for marketing authorization of individualized medicines at scale. By connecting treatment centers and diagnostic databases with its ASO library, EveryONE Medicines aims to expedite the time to treatment, with the goal of developing new ASO therapies in less than 12 months.

Technological Platform and Innovation

EveryONE Medicines distinguishes itself through its proprietary AI-driven design and development process for ASO therapies. This technology enables the rapid creation of individualized medicines that correct unique genetic variants causing devastating diseases. The company's approach includes:

Proprietary Technologies: Utilization of AI-enabled sequencing and design to develop ASO therapies efficiently.

Significant Scientific Methods: Application of antisense oligonucleotides designed to specifically target and modify RNA transcripts, aiming to slow down or halt disease progression.

By integrating these technologies, EveryONE Medicines is building a scalable solution to connect children with life-threatening neurodegenerative diseases to individualized therapies that target their specific genetic variants.

Leadership Team

EveryONE Medicines is led by a team of experienced professionals dedicated to advancing individualized precision therapeutics:

Kent Rogers, Chief Executive Officer: With 30 years of experience in the pharmaceutical and healthcare industries, Kent has held executive leadership positions at top-tier pharmaceutical companies and emerging biotech firms. His expertise includes brand and generic pharmaceuticals, specialty pharmacy, and healthcare supply chain management. Kent earned his MBA in International Business from Emory University's Goizueta Business School and a BS in Business Management & Organizational Change from Indiana University's Kelley School of Business.

Julia Vitarello, Co-founder: Inspired by her daughter Mila's journey with a rare neurodegenerative disease, Julia co-founded EveryONE Medicines to make individualized medicines like milasen scalable and accessible to rare disease patients worldwide. She also founded Mila's Miracle Foundation and co-founded the N=1 Collaborative, serving as a global scientific hub for individualized medicines.

Srinivas Chunduru, Chief Scientific Officer: Sri brings over 25 years of industrial experience in drug discovery and development across various therapeutic areas, including rare oncology. He has deep knowledge in conceptualizing ASO-based therapies and managing ASO pipelines. Sri earned his Ph.D. in Biochemistry from the University of Akron and completed post-doctoral fellowships at St. Jude Children's Research Hospital and the University of Pennsylvania.

Andrew Roddam, Chief Strategy Officer: Andrew has over 25 years of experience across academia, pharmaceutical, and life science companies, focusing on drug discovery and development. He received his DPhil in Statistics from the University of Oxford and has co-authored over 100 publications.

Deb Gouveia, Senior Vice President, Development Operations: With over 25 years of experience in drug development, Deb has expertise in clinical operations, regulatory affairs, quality assurance, and alliance management. She received her BS in Biology from the University of Massachusetts Boston.

Nicole P. Ouellette, Head of People Operations and Administration: Nicole brings over 18 years of experience in People Operations and Administration, having overseen strategies and policies in Human Resources, IT, Facilities, and Administration at various biotech companies. She received a BS in Business Administration and a Human Resource certification from Southern New Hampshire University.

Barbara Douglas, Senior Manager, Operations and Administration: Barbara has over three decades of administrative experience, supporting senior executives at various organizations. She is skilled at managing multiple projects and building working relationships with external stakeholders.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within the company's leadership team.

Competitor Profile

Market Insights and Dynamics

The market for individualized precision therapeutics, particularly for rare and ultra-rare diseases, is experiencing significant growth. Advancements in genetic sequencing and personalized medicine are driving the development of targeted therapies. The demand for treatments addressing unmet medical needs in pediatric neurodegenerative diseases presents substantial opportunities for companies like EveryONE Medicines.

Competitor Analysis

Key competitors in the field include:

BridgeBio Pharma: Focuses on developing therapies for genetic diseases and cancers, with a market capitalization of approximately $8.01 billion.

Revolution Medicines: Specializes in targeted therapies for RAS-addicted cancers, with a market capitalization of around $6.88 billion.

Vericel: Develops advanced cell therapies for sports medicine and severe burn care, with a market capitalization of approximately $2.10 billion.

These companies are engaged in developing targeted therapies for various conditions, contributing to the competitive landscape in the biotechnology sector.

Strategic Collaborations and Partnerships

EveryONE Medicines is honored to serve as a pilot for the UK's Rare Therapies Launch Pad (RTLP), working alongside multiple stakeholders, including the Medicines and Healthcare products Regulatory Agency (MHRA). This collaboration aims to model a scalable and sustainable system to meet the new era of individualized medicines, focusing on establishing an innovative regulatory and reimbursement pathway for rapid access to cutting-edge science by those who could benefit.

Operational Insights

EveryONE Medicines' strategic considerations include:

Major Competitors: Companies like BridgeBio Pharma, Revolution Medicines, and Vericel are developing targeted therapies for various conditions, contributing to the competitive landscape.

Market Position: By focusing on ultra-rare pediatric neurodegenerative diseases, EveryONE Medicines addresses a niche market with significant unmet needs, differentiating itself from competitors.

Distinct Competitive Advantages: The company's proprietary AI-driven design process, comprehensive ASO library, and strategic collaborations position it uniquely in the field of individualized precision therapeutics.

Strategic Opportunities and Future Directions

EveryONE Medicines' strategic roadmap includes:

Expansion of ASO Library: Continuing to develop and expand the library to cover a broader range of genetic variants.

Regulatory Pathway Development: Working closely with regulatory agencies to establish new approval pathways for individualized medicines.

Global Accessibility: Ensuring that individualized therapies are accessible to patients worldwide through scalable and sustainable solutions.

By leveraging its current strengths, EveryONE Medicines is well-positioned to achieve these objectives and make a significant impact in the field of personalized medicine.